Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-5: neoadjuvant trastuzumab, pertuzumab, and zongertinib without chemotherapy in HER2-positive breast cancer
2026-526214-93-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zongertinib, trastuzumab and pertuzumab in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence and severity of adverse events. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2026-526214-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526214-93-00.